Effectiveness and cost-effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility
This literature review of the effectiveness and cost-effectiveness of antenatal screening was conducted as part of a project evaluating the effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in EU/EEA Member States. The purpose of this review was to provide evidence for guidance to strengthen antenatal screening programmes in Europe.
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
5 Dec 2018 - The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
23 Nov 2018 - This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Programmatic management of latent tuberculosis infection in the European Union
15 Oct 2018 - Programmatic management of latent tuberculosis infection (LTBI) is a key component of the global tuberculosis (TB) elimination strategy. This document provides evidence-based guidance for the implementation of programmatic management of LTBI in the European Union and European Economic Area (EU/EEA).